Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of BI 765423 in Healthy Men
NCT06232252Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI-765423 in pulmonary fibrosis (PF) and idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects treated with BI 765423 who experience any treatment-emergent adverse event assessed as drug-related up to 159 days. Started May 2024; status: completed.
02
Drugs
BI-765423
03
Conditions
pulmonary fibrosis (PF)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06232252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232252.